Clinical trials that include the participation of patients are a key factor in improving patient treatment and care. Nevertheless, doctors and researchers often have difficulty in funding this type of trials.
To address this, the Novo Nordisk Foundation is establishing the Investigator Initiated Clinical Trials research programme to boost the opportunities to carry out clinical trials in Denmark. It will support trials that focus on developing new treatment methods or improving existing ones.
“Through this new programme, the Foundation wants to improve patient treatment by developing new drugs and diagnostic tools, new forms of surgery and other innovations to ensure that people receive the best quality care,” says Niels-Henrik von Holstein-Rathlou, Head of Research and Innovation Grants, Novo Nordisk Foundation.
The Investigator Initiated Clinical Trials research programme reflects the Foundation’s desire to support doctors’ own ideas instead of projects initiated by the pharmaceutical industry. Studies with an industrial or commercial purpose are therefore not eligible for grants.
The Programme is open to specialist physicians at hospitals in Denmark and will award grants totalling DKK 60 million per year. Applicants may apply for grants of DKK 5 million to 20 million.
The programme will for example support projects evaluating new treatment methods via clinical trials. These could include new methods for surgery or radiation therapy or combinations of treatments – or for example, whether the optimal treatment for an injured anterior cruciate ligament in a knee is surgery or physiotherapy and rehabilitation.
The programme is open for applications from 8 June 2017, with a submission deadline of 21 September 2017. Read more about the Investigator Initiated Clinical Trials research programme here.
Christian Mostrup Scheel, Senior Press Officer, email@example.com, +45 3067 4805